Extended release suspension compositions
US-2018221290-A1 · Aug 9, 2018 · US
US10238803B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10238803-B2 |
| Application number | US-201715853219-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 22, 2017 |
| Priority date | May 2, 2016 |
| Publication date | Mar 26, 2019 |
| Grant date | Mar 26, 2019 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present invention relates to a dual-chamber pack with a first chamber comprising a container; and a second chamber comprising a reservoir, a biphasic connector, a plunger, and a plug with a breakable polymeric membrane. The container of the first chamber is prefilled with a pharmaceutically acceptable vehicle and the reservoir of the second chamber is prefilled with a solid composition of an active ingredient, wherein the solid composition of the active ingredient is mixed with the pharmaceutically acceptable vehicle to form a liquid pharmaceutical composition upon activation of the dual-chamber pack.
Opening claim text (preview).
We claim: 1. A drug delivery device for the in situ preparation of an extended release oral suspension upon activation of the device, the device comprising: a) a first chamber comprising a suspension base; b) a second chamber comprising a solid composition comprising cores of active ingredient coated with a release controlling agent to form coated cores; and c) a breakable substantially impermeable polymeric membrane separating first and second chamber wherein, the substantially impermeable polymeric membrane is made up of a polymeric material selected from the group consisting of polyethylene (PE), low density polyethylene (LDPE), linear low density polyethylene (LLDPE), high density polyethylene (HDPE) and high barrier grade PE, has a thickness not less than 0.10 mm and a moisture vapor transmission rate less than about 5.0 g/m 2 /day; and wherein, the solid composition remains stable when stored in the drug delivery device at 40° C./75% RH for at least three months. 2. The drug delivery device of claim 1 , wherein the breakable substantially impermeable polymeric membrane prevents intimate contact between the contents of first and second chamber before activation. 3. The drug delivery device of claim 1 , wherein the second chamber comprises a plunger for storing the solid composition and a plug fitted with the breakable substantially impermeable polymeric membrane. 4. The drug delivery device of claim 3 , wherein after activation of the device, not more than 50% of the circumference of the breakable substantially impermeable polymeric membrane remains attached to the plug to allow free flow of the coated cores from second chamber to first chamber. 5. The drug delivery device of claim 3 , wherein the plunger comprises one or more sharp projections with an essential continuous blunt area at an angle of not more than 60°.
Organic compounds, e.g. fats, sugars · CPC title
Inorganic compounds · CPC title
Organic compounds, e.g. fats, sugars · CPC title
Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms · CPC title
Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches (A61K9/0007 takes precedence; eatable gels or foams A61K9/0056; oral mucosa adhesive forms A61K9/006) · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.